Molecular structure of Purvalanol A, CAS Number: 212844-53-6
Purvalanol A (CAS 212844-53-6)
See product citations (4)
Alternate Names:
6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine
Application:
Purvalanol A is a selective inhibitor of cyclin-dependent kinases
CAS Number:
212844-53-6
Purity:
≥99%
Molecular Weight:
388.89
Molecular Formula:
C19H25ClN6O
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Purvalanol A is a potent and selective inhibitor of cyclin-dependent kinases (CDKs). It functions by competitively binding to the ATP-binding site of CDKs. This inhibition leads to cell cycle arrest at the G2/M phase, ultimately suppressing cell proliferation. Purvalanol A may induce apoptosis in certain cancer cell lines by disrupting the cell cycle progression. Its mode of action involves the regulation of key proteins involved in cell cycle control, such as cyclins and CDK inhibitors. By targeting specific CDKs, Purvalanol A serves as a function for studying the molecular mechanisms underlying cell cycle regulation.
Purvalanol A (CAS 212844-53-6) References
- Cellular effects of purvalanol A: a specific inhibitor of cyclin-dependent kinase activities. | Villerbu, N., et al. 2002. Int J Cancer. 97: 761-9. PMID: 11857351
- Purvalanol A, inhibitor of cyclin-dependent kinases attenuates proliferation of cells in the dentate gyrus of the adult rat hippocampus. | Maćkowiak, M., et al. 2005. Pharmacol Rep. 57: 845-9. PMID: 16382206
- Purvalanol A enhances cell killing by inhibiting up-regulation of CDC2 kinase activity in tumor cells irradiated with high doses of X rays. | Iizuka, D., et al. 2007. Radiat Res. 167: 563-71. PMID: 17474786
- Purvalanol A induces apoptosis and downregulation of antiapoptotic proteins through abrogation of phosphorylation of JAK2/STAT3 and RNA polymerase II. | Iizuka, D., et al. 2008. Anticancer Drugs. 19: 565-72. PMID: 18525315
- Purvalanol A, a CDK inhibitor, effectively suppresses Src-mediated transformation by inhibiting both CDKs and c-Src. | Hikita, T., et al. 2010. Genes Cells. 15: 1051-62. PMID: 20825494
- Olomoucine II, but not purvalanol A, is transported by breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1). | Hofman, J., et al. 2013. PLoS One. 8: e75520. PMID: 24116053
- Purvalanol A is a strong apoptotic inducer via activating polyamine catabolic pathway in MCF-7 estrogen receptor positive breast cancer cells. | Obakan, P., et al. 2014. Mol Biol Rep. 41: 145-54. PMID: 24190492
- Purvalanol A, olomoucine II and roscovitine inhibit ABCB1 transporter and synergistically potentiate cytotoxic effects of daunorubicin in vitro. | Cihalova, D., et al. 2013. PLoS One. 8: e83467. PMID: 24376706
- Purvalanol induces endoplasmic reticulum stress-mediated apoptosis and autophagy in a time-dependent manner in HCT116 colon cancer cells. | Coker-Gürkan, A., et al. 2015. Oncol Rep. 33: 2761-70. PMID: 25901510
- The Cdc2/Cdk1 inhibitor, purvalanol A, enhances the cytotoxic effects of taxol through Op18/stathmin in non-small cell lung cancer cells in vitro. | Chen, X., et al. 2017. Int J Mol Med. 40: 235-242. PMID: 28534969
- The CDK inhibitor purvalanol A induces neutrophil apoptosis and increases the turnover rate of Mcl-1: potential role of p38-MAPK in regulation of Mcl-1 turnover. | Phoomvuthisarn, P., et al. 2018. Clin Exp Immunol. 192: 171-180. PMID: 29377076
- Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment. | Novotná, E., et al. 2018. Biochem Pharmacol. 156: 22-31. PMID: 30077642
- Purvalanol A induces apoptosis and reverses cisplatin resistance in ovarian cancer. | Zhang, X., et al. 2023. Anticancer Drugs. 34: 29-43. PMID: 35946506
Inhibitor of:
1700018G05Rik, 2410076I21Rik, 2610039C10Rik, 4930404A10Rik, 4930534B04Rik, 4931409K22Rik, 4933411G11Rik, 5830418K08Rik, ADCK4, ALS2CR7, ANKLE2, ANKRD20A1, ANKRD20A3, ANKRD52, APC8, ARPP-19, ASPM, BEND6, Beta-NAP, C-Nap1, C12orf28, C12orf50_1700017N19Rik, C12orf63, C16orf63_0610037P05Rik, C17orf55, C430048L16Rik, C6orf1, CC2D2A, CCDC77, CCNI2, CCNJL, CCRK, Cdc14, Cdc2, Cdc28, CDCrel-1, Cdk1, Cdk2, Cdk5, CENP-T, Centrobin, Cks2, Clb2, Clb3, COASTER, Collapsin Response Mediator Protein (CRMP), CPAN, CTAGE1, CTAGE2, CWF19L1, cyclin A-type, cyclin B, cyclin B1, cyclin C, cyclin F, cyclin G2, cyclin J, cyclin YL1, cyclin YL3, D-type cyclin, D14Ertd449e, DOC1, Dtl, Dyrk2, E2F-7, EG435366, EG624855, ENSA, FAM111B, FAM160A1, FAM44B, FLJ32549, fzr, GAK, GEMC1, Gm355, Gm606, Gm75, GMD, GPN3, GRK 7, Gtlf3b, H-plk, HAUS4, hCAP-G, HYLS1, Inv, KBP, KIAA0701, KIAA1009, KKIALRE, KPRP, LAGE-3, LIN-52, LIN37, LOC341346, LRRIQ1, MCEMP1, MDM1, MEIG1, MEIKIN, MIPU1, MKLP-1, Mog1p, MPc3_CBX8, Myt 1, Naglt1a, nArgBP2, NIF3L1 BP1, Nim1, NuMA, OIP5, OTTMUSG00000016588, Peregrin, Pho85, PISSLRE, PITSLRE A, PITSLRE B, POC5, POGZ, PPAN, PREI4, PRR19, Ran BP-3L, Repetin, ROGDI, rotatin, Rslcan-8, SAP 114, SERTAD4, Sil, Snk, SPANX-N1, SPC12, Speedy E3, Speedy E5, Speedy E6, TCHHL1, TEX27, THEG, Thrombospondin 4, TMEM194, TSGA10IP, V1RG1, WDR21, WDR24, WDR51B, WDR66, Wee 2, Xlr3a, ZBED5, ZC3H4, ZHX3, ZNF2, ZNF20, ZNF235, and ZWINT.Activator of:
APC4, Cables1, CCDC74A, Cdc11, Cdc5, Cdk10, Cdk3, CENP-O, Centriolin, CEP55, CEP63, Cig2, CLK1, CSAP, cyclin E, cyclin YL3, Dyrk4, EG624855, EML1, HAUS6, Hec1, IBRDC1, KIAA1671, KLHL38, NDR1, Nek5, NSL1, ORC3, p39, PISSLRE, PITSLRE B, Ran BP-4, RIOK1, Ska1, SMC4, SOLO, Spc25, SPDL-1, Speedy A, TSSK 1B, and ZNF81.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Purvalanol A, 1 mg | sc-224244 | 1 mg | $72.00 | |||
Purvalanol A, 5 mg | sc-224244A | 5 mg | $297.00 |